Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.35 |
| ▸ | DRD3 | P35462 | 4/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.35 |
| ▸ | HRH1 | P35367 | 2/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.35 |
| ▸ | HRH2 | P25021 | 2/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HTR6 | P50406 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21548014 | 1.00 | CYP2C9 (0.55) | CYP2C9LMNASLC6A2SLC6A3MAPK1 | |
| SCHEMBL22113161 | 1.00 | CYP2C9 (0.55) | CYP2C9LMNASLC6A2SLC6A3MAPK1 | |
| SCHEMBL1573636 | 1.00 | CYP2C9 (0.55) | CYP2C9LMNASLC6A2SLC6A3MAPK1 | |
| SCHEMBL13713095 | 1.00 | CYP2C9 (0.55) | CYP2C9LMNASLC6A2SLC6A3MAPK1 | |
| SCHEMBL372614 | 1.00 | CYP2C9 (0.55) | CYP2C9LMNASLC6A2SLC6A3MAPK1 | |
| SCHEMBL852253 | 1.00 | CYP2C9 (0.55) | CYP2C9LMNASLC6A2SLC6A3MAPK1 | |
| Hydrochloric Acid SCHEMBL704299 | 0.97 | LMNA (0.52) | CYP2C9LMNASLC6A2SLC6A3MAPK1 | |
| Hydrochloric Acid SCHEMBL7624931 | 0.97 | LMNA (0.52) | CYP2C9LMNASLC6A2SLC6A3MAPK1 | |
| Hydrochloric Acid SCHEMBL1110550 | 0.97 | LMNA (0.52) | CYP2C9LMNASLC6A2SLC6A3MAPK1 | |
| Hydrochloric Acid SCHEMBL3368724 | 0.97 | LMNA (0.52) | CYP2C9LMNASLC6A2SLC6A3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 857 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112654620-B | Novel pyrazolopyridine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2023-08-04 | — | — | CN | claimed |
| EP-3847173-B1 | NOVEL PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-04-12 | — | — | EP | claimed |
| US-20210355122-A1 | PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2021-11-18 | — | — | US | claimed |
| EP-3847173-A1 | NOVEL PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-07-14 | — | — | EP | claimed |
| CN-112654620-A | Novel pyrazolopyridine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2021-04-13 | — | — | CN | claimed |
| CN-110804051-A | Preparation method of granisetron intermediate | 杭州励德生物科技有限公司 | 2020-02-18 | — | — | CN | claimed |
| CN-102234231-B | 1-substituted-2-substituted-4- aryl substituted-butyl-2-alkene 1, 4-diketone compound, its preparation method and application | SHANGHAI INST MATERIA MEDICA | 2015-01-07 | — | — | CN | claimed |
| WO-2014130759-A1 | METHODS OF USING HISTAMINE RECEPTOR AGONISTS AND ANTAGONISTS | UNIVERSITY OF ROCHESTER (US) | 2014-08-28 | — | — | WO | claimed |
| CN-102234231-A | 1-substituted-2-substituted-4- aryl substituted-butyl-2-alkene 1, 4-diketone compound, its preparation method and application | SHANGHAI INST MATERIA MEDICA | 2011-11-09 | — | — | CN | claimed |
| JP-4658940-B2 | — | — | 2011-03-23 | — | — | JP | claimed |
| WO-2004089416-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| WO-2004089470-A2 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| WO-2004089415-A2 | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| US-20040058934-A1 | Heterocyclic compounds | JANSSEN PHARMACEUTIC, N.V. (BE) | 2004-03-25 | — | — | US | claimed |
| WO-2004022060-A2 | (1H-BENZOIMIDAZOL-2-YL)-(PIPERAZINYL)-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-03-18 | — | — | WO | claimed |
| CN-1451660-A | Process for preparing granisetron and its salt | HAIZHENG PHARMACEUTICAL CO LTD (CN) | 2003-10-29 | — | — | CN | claimed |
| EP-0422846-B1 | Aroyl-ureas | WYETH JOHN & BROTHER LTD (GB) | 1994-02-16 | — | — | EP | claimed |
| EP-0494978-A1 | HETEROCYCLIC COMPOUNDS. | WYETH JOHN & BROTHER LTD (GB) | 1992-07-22 | — | — | EP | claimed |
| WO-1991005783-A1 | HETEROCYCLIC COMPOUNDS | JOHN WYETH & BROTHER LIMITED (GB) | 1991-05-02 | — | — | WO | claimed |
| EP-0422846-A2 | Aroyl-ureas | JOHN WYETH & BROTHER LIMITED (GB) | 1991-04-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355122-A1 | PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | KCNJ1, KCNJ11, SSB | CYP2C9 907/4885LMNA 4444/4885SLC6A2 3179/4885 |
| US-20040058934-A1 | Heterocyclic compounds | HRH4, HRH2, HRH1 | CYP2C9 1552/4885LMNA 4780/4885SLC6A2 3850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.